Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. (Q54347651)

28 May 2018

title

Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. (English)

1 reference

28 May 2018

1 reference

1

Groop L

1 reference

28 May 2018

Schalin C

2

1 reference

28 May 2018

Franssila-Kallunki A

3

1 reference

28 May 2018

Widén E

4

1 reference

28 May 2018

Ekstrand A

5

1 reference

28 May 2018

Eriksson J

6

1 reference

28 May 2018

language of work or name

English

0 references

publication date

1 August 1989

1 reference

28 May 2018

American Journal of Medicine

published in

1 reference

28 May 2018

volume

87

1 reference

28 May 2018

issue

2

1 reference

28 May 2018

page(s)

183-190

1 reference

28 May 2018

Incidence and causes of secondary failure in treatment with tolbutamide. Experience with 2,500 patients treated up to five years

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Clinical pharmacology of oral antidiabetic agents (second of two parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

EXHAUSTION OF INSULOGENIC RESERVE IN MATURITY-ONSET DIABETIC PATIENTS DURING PROLONGED AND CONTINUOUS HYPERGLYCEMIC STRESS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Psychometric study of patient knowledge test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

The theoretical bases of indirect calorimetry: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Dynamics of water-isotope distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Influences of glucose loading and of injected insulin on hepatic glucose output

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Glucose-induced thermogenesis in nondiabetic and diabetic obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Predicting the Need for Insulin Therapy in Late Onset (40-69 Years) Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

C-peptide measurement in the differentiation of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Potentiation of Insulin Secretory Responses by Plasma Glucose Levels in Man: Evidence That Hyperglycemia in Diabetes Compensates for Impaired Glucose Potentiation*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Effect of insulin therapy on insulin resistance in type II diabetic subjects. Evidence for heterogeneity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Insulin treatment reverses the insulin resistance of type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980695-3

10.1016/S0002-9343(89)80695-3

7 January 2021

Identifiers

DOI

1 reference

28 May 2018

PubMed ID

2757059

1 reference

28 May 2018